Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter, Real-world Study on the Efficacy and Safety of Low-dose PEGylated Recombinant Human Granulocyte Colony-stimulating Factor (PEG rhG CSF) in Primary Prevention of Febrile Neutropenia (FN) in Cancer Patients After Chemotherapy

NCT07829276 is registered in ClinicalTrials.gov with Zhejiang Provincial People's Hospital as lead sponsor.

NCT NCT07829276
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07829276 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter, Real-world Study on the Efficacy and Safety of Low-dose PEGylated Recombinant Human Granulocyte Colony-stimulating Factor (PEG rhG CSF) in Primary Prevention of Febrile Neutropenia (FN) in Cancer Patients After Chemotherapy
Lead sponsor
Zhejiang Provincial People's Hospital
Phase
Observational
Overall status
Enrolling by invitation
Start date
November 1, 2026
Completion date
December 31, 2027
Enrollment
350 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant tumor